Silverback Therapeutics/$SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
$SPRY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
158
ISIN
US82835W1080
Website
SPRY Metrics
BasicAdvanced
$1.8B
-
-$0.16
0.94
-
Price and volume
Market cap
$1.8B
Beta
0.94
52-week high
$18.90
52-week low
$8.02
Average daily volume
1.4M
Financial strength
Current ratio
11.001
Quick ratio
10.354
Long term debt to equity
30.302
Total debt to equity
30.334
Profitability
EBITDA (TTM)
-26.72
Gross margin (TTM)
80.06%
Net profit margin (TTM)
-16.11%
Operating margin (TTM)
-27.87%
Effective tax rate (TTM)
-1.87%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-6.10%
Return on equity (TTM)
-6.91%
Valuation
Price to revenue (TTM)
18.239
Price to book
7.8
Price to tangible book (TTM)
8.06
Price to free cash flow (TTM)
-62.035
Free cash flow yield (TTM)
-1.61%
Free cash flow per share (TTM)
-29.34%
Growth
Revenue change (TTM)
971,120.00%
Earnings per share change (TTM)
-69.01%
3-year revenue growth (CAGR)
188.21%
3-year earnings per share growth (CAGR)
-40.06%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.
Bulls say / Bears say
Scotiabank initiated coverage of ARS Pharmaceuticals (SPRY) with a 'Sector Outperform' recommendation, suggesting a potential upside of over 200% from its current price. (nasdaq.com)
The merger between ARS Pharmaceuticals and Silverback Therapeutics has resulted in over $280 million in combined cash and securities, providing at least three years of operating runway to support the launch and commercialization of neffy® in the U.S., if approved. (nasdaq.com)
Raymond James initiated coverage of ARS Pharmaceuticals (SPRY) with an 'Outperform' recommendation, indicating confidence in the company's future performance. (nasdaq.com)
Silverback Therapeutics faced a securities lawsuit over its leading anti-tumor drug candidate, which was discontinued in 2022 due to efficacy concerns. (bloomberglaw.com)
Silverback Therapeutics' stock experienced a 2.9% decline, trading as low as $10.01, reflecting potential investor concerns. (marketbeat.com)
Analyst estimates project a net loss for ARS Pharmaceuticals in 2025, with an expected EPS of -$0.86, indicating potential financial challenges ahead. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
SPRY News
AllArticlesVideos
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $1.8B as of June 30, 2025.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of June 30, 2025.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.